Quarterly report pursuant to Section 13 or 15(d)

Revenue - Potential Milestone Payments (Details)

v3.21.2
Revenue - Potential Milestone Payments (Details) - Strategic Partnerships and Other License Agreements
$ in Millions
Jun. 30, 2021
USD ($)
Research, Development, Regulatory & Commercial Milestones  
Revenue Recognition, Milestone Method [Line Items]  
Total potential milestone payments $ 3,011
Research, Development, Regulatory & Commercial Milestones | AstraZeneca  
Revenue Recognition, Milestone Method [Line Items]  
Total potential milestone payments 1,096
Research, Development, Regulatory & Commercial Milestones | Servier  
Revenue Recognition, Milestone Method [Line Items]  
Total potential milestone payments 239
Research, Development, Regulatory & Commercial Milestones | Seagen  
Revenue Recognition, Milestone Method [Line Items]  
Total potential milestone payments 754
Research, Development, Regulatory & Commercial Milestones | Boston Pharmaceuticals  
Revenue Recognition, Milestone Method [Line Items]  
Total potential milestone payments 88
Research, Development, Regulatory & Commercial Milestones | Genentech  
Revenue Recognition, Milestone Method [Line Items]  
Total potential milestone payments 834
Sales Milestones  
Revenue Recognition, Milestone Method [Line Items]  
Total potential milestone payments 5,804
Sales Milestones | AstraZeneca  
Revenue Recognition, Milestone Method [Line Items]  
Total potential milestone payments 4,275
Sales Milestones | Servier  
Revenue Recognition, Milestone Method [Line Items]  
Total potential milestone payments 214
Sales Milestones | Seagen  
Revenue Recognition, Milestone Method [Line Items]  
Total potential milestone payments 450
Sales Milestones | Boston Pharmaceuticals  
Revenue Recognition, Milestone Method [Line Items]  
Total potential milestone payments 265
Sales Milestones | Genentech  
Revenue Recognition, Milestone Method [Line Items]  
Total potential milestone payments $ 600